Kyverna Therapeutics(US:KYTX) Globenewswire·2025-09-15 17:02Core Insights - Kyverna Therapeutics is set to present interim data from the Phase 2 portion of the KYSA-6 study for KYV-101 in myasthenia gravis at the AANEM Annual Meeting scheduled for October 29 – November 1, 2025 [1][2] - The company is preparing to initiate the registrational Phase 3 portion of the KYSA-6 trial by the end of 2025 [1][2] - KYV-101 is a fully human, autologous CD19 CAR T-cell therapy aimed at treating B-cell-driven autoimmune diseases, with potential for durable drug-free, disease-free remission [3][4] Company Overview - Kyverna Therapeutics focuses on developing cell therapies for autoimmune diseases and is advancing its lead candidate, KYV-101, through late-stage clinical development [4] - The company is also conducting registrational trials for stiff person syndrome and myasthenia gravis, along with ongoing multi-center Phase 1/2 trials for lupus nephritis [4] - Kyverna is exploring additional indications for its therapies, including multiple sclerosis and rheumatoid arthritis, to inform future development priorities [4] Clinical Trial Details - The KYSA-6 Phase 2 study is an open-label, single-arm, multicenter trial that has been amended into a registrational Phase 2/3 study following FDA alignment [2] - Interim results to be presented will include top-line efficacy and safety data for six patients, with follow-up data extending up to nine months [2][3] - The presentation will be led by Dr. Srikanth Muppidi on October 29, 2025, at 11:00 AM PT [3]